Tumors of female reproductive system

Опухоли женской репродуктивной системы

1994-40981999-8627

Publishing House ABV Press

816

10.17650/1994-4098-2021-17-1-65-69

GYNECOLOGY. TREATMENT

ГИНЕКОЛОГИЯ. ЛЕЧЕНИЕ

Proceedings of the Expert Council “Treatment of inoperable endometrial cancer in Russia: issues that have not yet been addressed”

Материалы заседания экспертного совета «Нерешенные вопросы в лечении неоперабельного рака эндометрия в России»

16062021

171

65691606202116062021

https://ojrs.abvpress.ru/ojrs/article/view/816

1. Инструкция по медицинскому применению лекарственного препарата Ленвима® (Lenvima®). Регистрационное удостоверение ЛП-003398 с изменениями от 10.06.2020. [Medication package insert for Lenvima®. Registration number LP-003398 with amendments dated 10.06.2020. (In Russ.)].

Инструкция по медицинскому применению лекарственного препарата Ленвима® (Lenvima®). Регистрационное удостоверение ЛП-003398 с изменениями от 10.06.2020. [Medication package insert for Lenvima®. Registration number LP-003398 with amendments dated 10.06.2020. (In Russ.)].

2. Stelloo E., Bosse T., Nout R.A. et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 2015;28:836–44. DOI: 10.1038/modpathol.2015.43.

Stelloo E., Bosse T., Nout R.A. et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 2015;28:836–44. DOI: 10.1038/modpathol.2015.43.

3. Нечушкина В.М., Коломиец Л.А., Кравец О.А. и др. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли: Практические рекомендации RUSSCO № 3s2, 2019 (том 9). С. 218–232. [Nechushkina V.M., Kolomiets L.A., Kravets O.A. et al. Practical guideline for pharmacotherapy of uterine cancer and uterine sarcoma. Malignant tumors: practical guideline by RUSSCO № 3s2, 2019 (vol. 9). Pp. 218–232. (In Russ.)].

Нечушкина В.М., Коломиец Л.А., Кравец О.А. и др. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли: Практические рекомендации RUSSCO № 3s2, 2019 (том 9). С. 218–232. [Nechushkina V.M., Kolomiets L.A., Kravets O.A. et al. Practical guideline for pharmacotherapy of uterine cancer and uterine sarcoma. Malignant tumors: practical guideline by RUSSCO № 3s2, 2019 (vol. 9). Pp. 218–232. (In Russ.)].

4. Клинические рекомендации АОР 2020. Рак тела матки и саркомы матки. Доступно по: https://oncology-association.ru/files/clinical-guidelines-2020/rak_tela_matki_i_sarkomy_matki.pdf. [Clinical guideline by the Russian Association of Oncologists 2020. Uterine cancer and uterine sarcoma. Available at: https://oncology-association.ru/files/clinical-guidelines-2020/rak_tela_matki_i_sarkomy_matki.pdf. (In Russ.)].

Клинические рекомендации АОР 2020. Рак тела матки и саркомы матки. Доступно по: https://oncology-association.ru/files/clinical-guidelines-2020/rak_tela_matki_i_sarkomy_matki.pdf. [Clinical guideline by the Russian Association of Oncologists 2020. Uterine cancer and uterine sarcoma. Available at: https://oncology-association.ru/files/clinical-guidelines-2020/rak_tela_matki_i_sarkomy_matki.pdf. (In Russ.)].

5. Cancer Genome Atlas Research Network, Kandoth C., Schultz N. et al. Integrated genomic characterization of endometrial carcinoma [published correction appears in Nature 2013;500(7461):242]. Nature 2013;497(7447):67–73. DOI: 10.1038/nature12113.

Cancer Genome Atlas Research Network, Kandoth C., Schultz N. et al. Integrated genomic characterization of endometrial carcinoma [published correction appears in Nature 2013;500(7461):242]. Nature 2013;497(7447):67–73. DOI: 10.1038/nature12113.

6. Pakish J.B., Zhang Q., Chen Z. et al. Immune microenvironment in microsatellite-instable endometrial cancers: hereditary or sporadic origin matters. Clin Cancer Res 2017;23: 4473–81. DOI: 10.1158/1078-0432.CCR-16-2655.

Pakish J.B., Zhang Q., Chen Z. et al. Immune microenvironment in microsatellite-instable endometrial cancers: hereditary or sporadic origin matters. Clin Cancer Res 2017;23: 4473–81. DOI: 10.1158/1078-0432.CCR-16-2655.

7. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64. DOI: 10.1038/nrc3239.

Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64. DOI: 10.1038/nrc3239.

8. Базаева И.Я., Хохлова С.В., Феденко А.А. Лекарственное лечение рецидивов и диссеминированного рака тела матки. Сибирский онкологический журнал 2018;17(1):55–63. [Bazaeva I.Ya., Khokhlova S.V., Fedenko A.A. Pharmacotherapy of recurrent and disseminated uterine cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2018;17(1):55–63. (In Russ.)]. DOI: 10.21294/1814-4861-2018-17-1-55-63.

Базаева И.Я., Хохлова С.В., Феденко А.А. Лекарственное лечение рецидивов и диссеминированного рака тела матки. Сибирский онкологический журнал 2018;17(1):55–63. [Bazaeva I.Ya., Khokhlova S.V., Fedenko A.A. Pharmacotherapy of recurrent and disseminated uterine cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2018;17(1):55–63. (In Russ.)]. DOI: 10.21294/1814-4861-2018-17-1-55-63.

9. Нечушкина В.М., Морхов К.Ю., Кузнецов В.В. Эволюция лечения рака тела матки. Злокачественные опухоли 2016;4(спецвыпуск 1):92–8. [Nechushkina V.M., Morkhov K.Yu., Kuznetsov V.V. Evolution of treatment for uterine cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;4(special issue 1):92–8. (In Russ.)].

Нечушкина В.М., Морхов К.Ю., Кузнецов В.В. Эволюция лечения рака тела матки. Злокачественные опухоли 2016;4(спецвыпуск 1):92–8. [Nechushkina V.M., Morkhov K.Yu., Kuznetsov V.V. Evolution of treatment for uterine cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;4(special issue 1):92–8. (In Russ.)].

10.

10. Makker V., Green A.K., Wenham R.M. et al. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract 2017;4:19. DOI: 10.1186/s40661-017-0056-7.

Makker V., Green A.K., Wenham R.M. et al. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract 2017;4:19. DOI: 10.1186/s40661-017-0056-7.

11.

11. Suyama K., Iwase H. Lenvatinib: A promising molecular targeted agent for multiple cancers. Cancer Control 2018;25(1):1073274818789361. DOI: 10.1177/1073274818789361.

Suyama K., Iwase H. Lenvatinib: A promising molecular targeted agent for multiple cancers. Cancer Control 2018;25(1):1073274818789361. DOI: 10.1177/1073274818789361.

12.

12. Capozzi M., De Divitiis C., Ottaiano A. et al. Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 2019;11:3847–60. DOI: 10.2147/CMAR.S188316.

Capozzi M., De Divitiis C., Ottaiano A. et al. Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 2019;11:3847–60. DOI: 10.2147/CMAR.S188316.

13.

13. Incio J., Tam J., Rahbari N.N. et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res 2016;22(12):2993–3004. DOI: 10.1158/1078-0432.CCR-15-1839.

Incio J., Tam J., Rahbari N.N. et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res 2016;22(12):2993–3004. DOI: 10.1158/1078-0432.CCR-15-1839.

14.

14. Ott P.A., Hodi F.S., Buchbinder E.I. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015;5:202.

Ott P.A., Hodi F.S., Buchbinder E.I. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015;5:202.

15.

15. Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. DOI: 10.1056/NEJMoa1816714.

Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. DOI: 10.1056/NEJMoa1816714.